Company Overview
Frequency Therapeutics (FREQ) is a clinical-stage company targeting sensorineural hearing loss ((SNHL)). SNHL, currently, affects more than 40M people in the US and that number is expected to grow by 20% over the next decade, representing a substantial domestic market. The company is currently in a Phase IIa clinical trial in their lead program. With readouts expected in the 1H 2021, their stock is likely to have major moves between now and then. With the vast majority of their value tied to the outcome of this trial, positive data could send